Structure-activity relationship study of novel 2-aminobenzofuran derivatives as P-glycoprotein inhibitors

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Pharmacology

Background:

• Chemotherapy resistance in cancer is a significant clinical challenge.
• Multidrug resistance (MDR) is often mediated by P-glycoprotein (P-gp) overexpression.
• Developing effective P-gp inhibitors is crucial for overcoming MDR.

Purpose of the Study:

• To synthesize and evaluate novel 2-aminobenzofuran derivatives as P-gp modulators.
• To assess the in vitro efficacy of these compounds in overcoming P-gp mediated MDR.
• To identify lead compounds for further structural optimization.

Main Methods:

• Synthesis of novel 2-aminobenzofuran derivatives.
• In vitro testing of compounds for P-gp inhibitory activity.
• Evaluation of compound-mediated sensitization of MDR cancer cells to chemotherapeutic agents (vincristine, paclitaxel, doxorubicin).

Main Results:

• Compound 43 demonstrated significant P-gp inhibitory activity, increasing it 11.12-fold at 5 μM.
• Compound 43 was 3.6-fold more potent than verapamil, a known P-gp inhibitor.
• At 2.5 μM, compound 43 sensitized MDR cells (Flp-In™-293/MDR and KBvin) to vincristine, paclitaxel, and doxorubicin by varying degrees.

Conclusions:

• Novel 2-aminobenzofuran derivatives show promise as P-gp inhibitors.
• Compound 43 is a potent modulator of P-gp activity and sensitizes resistant cancer cells to multiple chemotherapeutics.
• This study provides a foundation for developing optimized P-gp inhibitors to combat cancer MDR.